Background: Technological advances can improve care and outcomes but are a primary driver of health care spending growth. Understanding diffusion and use of new oncology therapies is important, given substantial increases in prices and spending on such treatments.
T echnological advances have provided substantial improvements in health that are recognized to be of reasonable value, 1 and evidence suggests that rapid adoption of cost-effective innovations is associated with better outcomes. 2 Nevertheless, technological advances are generally accepted as the primary driver of health care spending growth, [3] [4] [5] and thus, understanding variations in diffusion and use of new technologies are instructive in light of efforts to improve the value of health care.
Understanding diffusion of new cancer therapies is of particular interest, given substantial increases in the prices of cancer drugs newly approved by the Food and Drug Administration (FDA) 6 and rising spending on cancer drugs by insurers and patients. 7, 8 Moreover, new infused cancer drugs typically are covered by insurers, and reimbursement is often greater for higher-priced drugs; for example, oncology practices are currently reimbursed 104.3% of the average sales price for infused drugs for Medicare beneficiaries. 9 Prior research has documented wide variation across oncology practices in Medicare expenditures for cancer care, including chemotherapy, 10 suggesting broad opportunities for providers to improve the value of cancer care delivered, defined as health outcomes achieved per dollar spent. 11 The American Society of Clinical Oncology 12, 13 and others 14 now encourage providers to consider value in cancer treatment decisions by evaluating the clinical benefit, toxicity, and cost of treatments. 12 Moreover, recent efforts seeking to improve the delivery of high-value cancer care, including the CMS Oncology Care Model, have been targeted at practices. [15] [16] [17] Nevertheless, few studies have explored practice-level variation in use and diffusion of new cancer treatments; such information could inform the likelihood of success of policies and interventions targeting providers.
We studied diffusion of one of the first widely-used biologic cancer therapies-bevacizumab-across oncology practices. Bevacizumab was a novel treatment when initially approved by the FDA for advanced-stage colorectal cancer in February 2004 and since has been approved for treating advanced cancers of the lung, breast, brain, kidney, cervix, and ovary, allowing assessment of diffusion by indication (see Supplemental Materials Table 1 , Supplemental Digital Content 1, http://links.lww.com/MLR/B494, for exact indications). Moreover, the benefits of bevacizumab vary by cancer type; it has been shown to improve median overall survival for patients with metastatic colorectal cancer (20.3 mo vs. 15.6 mo for regimens with vs. without bevacizumab) 18 and lung cancer (12.3 mo vs. 10.3 mo), 19 but improves only progression-free survival, not overall survival, for patients with breast, [20] [21] [22] [23] kidney, 24 glioblastoma of the brain, 25, 26 and ovarian cancers. 27, 28 Using Medicare data from 2004-2012, we assessed differences in diffusion of bevacizumab in oncology practices treating Medicare patients across the United States overall and by cancer type. In addition, we sought to understand variation in bevacizumab use across oncology practices overall and for higher versus lower-value indications. Finally, we identified patient and practice characteristics associated with use of bevacizumab.
METHODS

Data and Patients
We used Medicare data for a random 20% sample of fee-for-service Medicare beneficiaries aged 65 years or above in 2004 through 2012 (the most recent data available at the time of the study). We excluded Medicare beneficiaries less than 65 years of age because they are eligible based on disability and their patterns of care may differ from other patients of the same age and older Medicare beneficiaries. We identified individuals with at least 2 outpatient office visits at least (30 d apart) with a cancer diagnosis in a calendar year during 2005-2012 who received outpatient infused chemotherapy (Supplemental Digital Content Table 2 , Supplemental Digital Content 1, http://links.lww.com/MLR/B494). Using International Classification of Disease, ninth Edition (ICD9) diagnosis codes, we characterized cancer type as colorectal, lung, breast, brain, kidney, ovary, and other (all other cancer types) based on visits in the 6 months before and after the first chemotherapy claim in a calendar year (if > 1 cancer type in that period, they were assigned to the diagnosis coded most frequently, or most recently if a tie). Cervical cancer, for which bevacizumab is also approved, is infrequent among Medicare beneficiaries and was categorized with other cancers. The study was approved by the Harvard Medical School Human Subjects Committee.
Bevacizumab and Other Intravenous Chemotherapy
For each patient in each month, we documented receipt of infused chemotherapy (Supplemental Digital Content Table 2, Supplemental Digital Content 1, http://links.lww.com/ MLR/B494). We identified an "episode" of chemotherapy as long as there was no break of > 3 months; patients who had > 3 months without chemotherapy and started again were considered to have a second episode. Bevacizumab use was defined by Healthcare Common Procedure Coding System code J9035 at any time during an episode. Although bevacizumab was approved in 2004, its use could not be observed until January 2005 when the billing code was available. To avoid identifying bevacizumab for ophthalmic use, we required a cancer diagnosis code on the bevacizumab claim.
We characterized bevacizumab use as "higher value" when used for cancers for which an overall survival benefit had been demonstrated. Higher-value indications included colorectal cancer throughout the study period and lung cancer after presentation of trial findings demonstrating an overall survival benefit with bevacizumab in May 2005 29 [results were similar when using the publication date of the trial findings (December 2006) 19 and are not presented]. Although the overall survival benefits are modest (ie, 2 mo improvement in median survival for patients with nonsmall cell lung cancer), they are consistent with other widely adopted-therapeutic improvements in oncology. Use for other cancer types or for lung cancer before May 2005 was considered lowervalue. We also characterized bevacizumab use as approved versus not approved based on FDA approval for that cancer type; this is distinct from higher-value use because in some cases FDA approval was based on progression-free survival benefit without overall survival benefit. FDA-approved indications included colorectal cancer at all times, lung cancer after October 2006, breast cancer from February 2008 through November 2011, glioblastoma after May 2009, and kidney cancer after July 2009. All other indications were nonapproved, including ovarian cancer (FDA-approved in 2014). We approximated "higher-value" and FDA-approved use based on cancer type, recognizing that we lacked information on stage, line of therapy, and histology to assess use exactly according to the FDA-labeled indication.
Identifying Practices
Each patient was assigned for each year to an oncology practice [identified using tax identification numbers (TINs)] based on the plurality of office visits (evaluation and management codes 99201-99215, 99241-99245, G0402, G0438, G0438) with physicians with specialty codes for medical oncology, hematology/oncology, or gynecologic oncology. Patients with equal numbers of visits to > 1 practice were assigned to the practice with the greater sum of allowed charges. We excluded very-low-volume practices, restricting our sample to practices providing chemotherapy to ≥ 8 patients in our 20% Medicare data per year, representing an average of 40 Medicare patients per practice. These practices included 55% of physicians and 95% of patients (Supplemental Digital Content Table 3 , Supplemental Digital Content 1, http://links.lww.com/MLR/B494).
Practice and Patient Characteristics
We identified practices affiliated with an academic medical center based on work by Welch and Bindman 30 ; other practices were classified as independent or hospital-owned (a time-varying variable where practices were considered hospital-owned in a year if > 75% of the practices' claims in that year had a place of service code for the outpatient hospital; practices can bill in this manner whether on-campus or offcampus). 31 We also characterized the proportion of a practice's patients residing in high-poverty zip codes using 2010 census data. Finally, for each practice we determined the number of physicians, the number of oncologists, and the ratio of oncologists to all physicians billing in the practice over all patients in the 20% Medicare fee-for-service sample. We hypothesized that diffusion would be faster in academic practices because of their engagement in testing novel therapies in clinical trials. We hypothesized that use of bevacizumab would be greater in independent versus hospital-based practices because of the greater financial incentives for use.
For each patient in each episode, we characterized age, race/ethnicity, sex, cancer type, diagnosis codes suggesting metastatic cancer (ICD9 codes 196-199.0), year, Charlson comorbidity score, 32, 33 Census division, and zip-code level measures of median household income, proportion of residents living in poverty, and proportion of residents who graduated from high school. We also characterized whether the episode was the first versus second or later episode. Patient and practice-level variables were categorized as in Table 1 . Patients with missing race/ethnicity data were grouped with the "other" category. A total of 242 patients (0.1%) with missing zip codes were excluded from analyses.
Diffusion of Bevacizumab
We described diffusion, defined as the cumulative percentage of bevacizumab adopters over time, following Rogers' diffusion of innovation theory 34 and focusing on practices as the unit of interest. Similar to others, [35] [36] [37] [38] we examined the pace of bevacizumab adoption in practices at a given time. For each practice, we assessed time to first use of bevacizumab and time to 10% use. The latter was defined as the time from January 2005 to the month in which bevacizumab was used in 10% of cumulative patients receiving chemotherapy in the practice. 36 Time to 10% use may represent more routine use and avoids characterizing diffusion rates based on a single infusion in a practice; we would not expect substantially greater use in most practices because only a subset of cancer patients receiving chemotherapy are eligible for bevacizumab. We also assessed time to 50% use; very few practices treated ≥ 50% of potentially-eligible patients based on cancer type with bevacizumab, and thus we focused on time to first use and time to 10% use.
Analyses Diffusion
We plotted cumulative time to first use and 10% use in practices by month for patients with each cancer type. 31 We also plotted diffusion stratified by academic versus hospitalowned versus independent practices and large practices ( ≥ 20 Medicare patients treated per year in our 20% Medicare sample) versus small practices (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) Medicare patients treated in a year in our 20% sample).
Modeling Speed of Diffusion (Time to Use) Across Practices
In a subset of practices with at least one patient with colorectal, lung, and breast cancer in the 20% Medicare sample in 2005, we estimated frailty models with multivariate event times to determine the extent to which a practice's time to first use for 1 type of cancer is correlated with its time to first use for other cancer types. 39 These models included a random effect for each practice and permit modeling of multivariate, dependent, "failure" times. We used Kendall's Tau to estimate the correlation between bevacizumab use for different cancer types within the same practice. We also assessed the association of practice characteristics described above with time to bevacizumab adoption by hazard ratios.
Bevacizumab Use and Between-practice Variation
We used hierarchical models with practice random effects to estimate the between-practice variation in the probability of a patient receiving bevacizumab in a given episode, net of sampling error. Models adjusted for all patient and practice characteristics described above. We characterized the variation by exponentiating differences in the random intercepts (log odds of bevacizumab use) for a practice one standard deviation above the mean (higher-use practice) versus a practice 1 SD below the mean (lower-use practice). 40 We also assessed whether the between-practice variation in bevacizumab use differed for patients receiving bevacizumab for higher-value versus lower-value indications, for FDAapproved versus non-FDA-approved indications, and for larger versus smaller practices.
Because practice variation in use may differ once practices reach a "steady state" of use, we assessed if models examining bevacizumab use differed between the early study period (2005) (2006) (2007) (2008) and late study period (2009-2012). Results were similar to our primary analyses and are not presented.
Sensitivity Analyses
Bevacizumab was first approved in 2004, but there was no procedure code for bevacizumab until 2005; rather before 2005 practices used the nonspecific J9999 code (antineoplastic drugs not otherwise classified) for bevacizumab. To assess if diffusion curves would have been similar if we had reliable data on its use in 2004, we recalculated the diffusion curves beginning in 2004 using code J9999 among patients with colorectal cancer, who comprised the vast majority of patients for whom this non-specific code was used in 2004.
Two-sided P-values <0.05 were considered statistically significant. Analyses were performed using SAS Statistical Software, Version 9.4 (Cary, NC), R version 3.3.2, and RStudio version 1.0.136.
RESULTS
The study population included 236,304 patients who received infused chemotherapy during 2005-2012 and were treated in 2329 practices. These patients had 307,746 chemotherapy episodes. The mean patient age was 74.1 years (SD, 6.1), 53% were female, and 90% were white (Table 1) . The practices included 156,839 physicians of whom 10, 196 were oncologists. The median [interquartile (IQ) range] number of physicians in the practices was 6 (2-48), the median (IQ range) number of oncologists was 3 (1-5), the mean proportion of oncologists was 82% (range, 7%-100%). Of the 2329 practices, 6% were academic, 14% were nonacademic hospital-owned, and 80% were independent. Approximately 3-quarters (78%) of patients were in nonacademic, independent practices. Overall, patients received bevacizumab in 8.5% of chemotherapy episodes. Use was greatest for episodes with cancer types with evidence for overall survival benefit (20.0% of episodes) and for cancer types that were FDA-approved without overall survival benefit (10.8% of episodes) or for cancer types that would be or previously were FDA-approved (6.3% of episodes) than for other cancer types (0.8% of episodes). All continuous variables are centered at the mean, so differences reflect increases per unit above the mean. *An episode is defined as a new initiation of chemotherapy after 3 months without any chemotherapy. †Reflects change per each $1000 increase above the mean. ‡Reflects change per 10% increase above the mean. ¶Omitted from model because collinear with number of oncologists and ratio of oncologists to all physicians, which were both included. patients with colorectal cancer (green triangles), the first approved indication; nearly half of practices used bevacizumab for at least 1 patient by January 2006. Use by practices for at least one patient with lung, breast, ovarian, kidney, and brain cancers all preceded FDA approvals by many months. More than 30% of practices had used bevacizumab for at least 10% of colorectal cancer patients by July 2005 (Fig. 2) . The proportion of practices using bevacizumab for 10% of patients was lower for other cancers, particularly breast, kidney, and ovarian cancers, all lowervalue indications. An exception was glioblastoma of the brain (a cancer with few approved treatments), where > 50% of practices had used bevacizumab for 10% of patients receiving chemotherapy within 30 months of FDA-approval. Time to first use of bevacizumab was more rapid among academic and independent than hospital-owned practices (Supplemental Digital Content Fig. 1 
Diffusion of Bevacizumab
Modeling Speed of Diffusion Across Practices
The frailty models confirmed that time to first bevacizumab use was faster for colorectal cancer than breast or lung cancer ( Table 2 ). The Kendall τ was 0.29, suggesting moderate correlation between bevacizumab use for different cancer types within the same practice. Speed of diffusion was faster among practices with more oncologists, a higher ratio of oncologists to other physicians, and independent versus academic practices.
Use of Bevacizumab and Between-practice Variation
Our hierarchical models identified substantial variation in the probability of bevacizumab use across practices. The odds ratio (95% confidence interval) of bevacizumab use was 2.90 (2.73-3.08) for a practice 1 SD above the mean versus a practice 1 SD below the mean (after adjusting for patient and practice characteristics) ( Compared with independent practices, patients treated at academic and nonacademic hospital-owned practices had lower odds of receiving bevacizumab (Table 1 , right columns). Patients at practices with a higher ratio of oncologists to all physicians had higher odds of receiving bevacizumab. Older patients, patients with cancers other than colorectal and brain cancers, and those with greater comorbidity had lower odds of use. Bevacizumab use was more likely for non-Hispanic black versus non-Hispanic white patients as well as patients living in areas with higher 
DISCUSSION
We observed relatively rapid diffusion of bevacizumab across 2329 practices providing infused chemotherapy to Medicare beneficiaries with cancer, particularly for patients with colorectal cancer, the first cancer for which it was FDAapproved. Diffusion was also somewhat rapid for treatment of other cancer types, even before FDA approval for those cancers.
The relatively high off-label diffusion of bevacizumab is consistent with other evidence of frequent off-label drug use in oncology. 41 Diffusion was more rapid for lung cancer (a higher-value use) than for breast or kidney cancers, consistent with the documented overall survival benefit for lung cancer. Other evidence of declining use of bevacizumab following the FDA's withdrawal of its breast cancer indication 42 also supports physicians' responsiveness to emerging evidence. Nevertheless, bevacizumab continues to be included in breast cancer guidelines, 43 and off-label use is typically covered by insurers, including Medicare. Policies requiring evidence development as a condition for insurance coverage of off-label chemotherapy use might inform our understanding of use and outcomes of these drugs in nontrial patient populations.
The substantial variation in bevacizumab use across oncology practices suggests that the likelihood of a patient receiving bevacizumab depends on the practice where they obtain care. This variation was particularly evident for lower-value versus higher-value indications and for nonapproved versus approved cancer types. This substantial between-practice variation suggests that practices influence treatment decisions, practice patterns diffuse within practices, or oncologists sort to practices exhibiting similar practice patterns. Thus, interventions aimed at practices have potential for increasing highvalue use and decreasing low-value use of high-cost therapies by prompting changes in practice management or focusing efforts to improve care delivery on inefficient practices. Initiatives such as Accountable Care Organizations and the CMS Oncology Care Model, 17 which provides episode payments for chemotherapy combined with performance-based payments for meeting spending and quality targets, may be successful if they encourage practices to focus on appropriate use of high-cost therapies. Expanded use of clinical pathways that prioritize use of chemotherapy regimens that maximize clinical benefit and value is one promising strategy. 44 Nevertheless, some 45 have argued against the inclusion of drug costs in alternate payment models such as the Oncology Care Model because of concern about inadequate clinical data to assure patients with targetable mutations are treated appropriately with targeted therapies and because spending on chemotherapy explains substantially less of the variation in cancer care expenditures than acute hospital care and postacute care. 46 Finally, we documented differences in bevacizumab use by practice and patient characteristics. We observed greater use of bevacizumab in independent versus hospitalowned and academic practices. Hospital-based physicians are less likely than other physicians to report financial incentives for prescribing chemotherapy, 47 likely because any profits from drug purchase and resale are realized by hospitals rather than physicians directly. Approximately one-third of oncology practice revenue reflects net drug revenue (total revenue from drugs less the cost of purchasing drugs) 48 and evidence suggests that oncologists responded to the Medicare Modernization Act's 2003 reduced payment rates for oncology drugs by decreasing use of less-profitable drugs and increasing use of more profitable (often higherpriced) drugs, 49 although these differences varied across geographic regions. 50 Another study of patients with colorectal cancer found increased adoption of newly approved agents (including bevacizumab) for individuals with metastatic colorectal cancer following the Medicare Modernization Act, which was accelerated in physician offices relative to hospital outpatient department settings. 51 An alternate explanation is that independent practices may be able to respond more rapidly to evolving evidence.
We found greater use of bevacizumab among younger patients, those with less comorbidity, and those likely to have metastatic cancers, reflecting use among patients for whom the benefit to harm ratio is greatest. We observed greater use among black versus white patients, possibly reflecting more advanced stage of disease, 52 for which we were unable to adjust because we lacked reliable information on cancer stage. The greater use among individuals in high-income areas suggests that nonclinical factors are also influencing use of new therapies.
Our study has several limitations. We lacked information about patients' cancer stage, histology, and performance status, limiting our ability to precisely understand which patients received bevacizumab according to FDA indications, and we were unable to determine the extent to which diffusion was prompted by FDA approvals, release of promising clinical data, or physicians' experimentation with off-label drugs in hopes of benefit. Nevertheless, the greater use for indications with stronger evidence of benefit suggests that physicians were responding to evidence. The lack of rich clinical data also limited our ability to adjust for differences in case mix across practices (although adjustment for patient-level covariates did not decrease the betweenpractice variation). We used diagnosis codes to infer metastatic stage, which may be inaccurate. 53 We identified practices based on TINs, which may be imperfect markers of physicians who practice together, and we had limited information about practice characteristics. For example, we lacked information about whether any of the academic or hospital-owned practices were eligible for discounts under the 340B program or whether independent practices were affiliated with eligible hospitals, which could encourage their affiliated practices to refer patients to hospital-based infusion suites for chemotherapy. 54 Finally, we studied only older patients enrolled in fee-for-service Medicare; patterns of care may differ for younger or privately-insured patients. However, because nearly all oncology practices accept Medicare and because the solid tumors for which bevacizumab is indicated are common in older individuals, our analysis represents a generalizable approach to characterizing bevacizumab diffusion.
In conclusion, we observed relatively rapid diffusion of bevacizumab and substantial variation of bevacizumab use across oncology practices, particularly for lower-value uses and nonapproved indications of the drug. These findings suggest that interventions targeted at the practice level have potential for decreasing overuse of high-cost, and potentially lower-value, therapies.
